Objectives-To determine which heat shock proteins (hsps) are overexpressed in systemic lupus erythematosus (SLE), and to examine the relevance of these findings to clinical disease activity. Methods-Hsp levels in peripheral blood mononuclear cells (PBMC) of patients with SLE and normal controls were measured. Levels were analysed with respect to detailed clinical activity scores. Other hsps were also quantified in 30-50% of these samples. Results-There was significant increase of the 90 kilodalton heat shock protein (hsp90) in patients with SLE and active neuropsychiatric (p<0005) and cardiorespiratory (p<001) disease. There was also significant increase of the inducible 72 kilodalton member (hsp72), but not the constitutive 73 kilodalton member (hsp73) of the hsp70 family, and no increase of the 60 kilodalton hsp (hsp6O) was seen in patients compared with controls. There was no association of hsp72 with disease activity, and no correlation between hsp90 and hsp72 levels was seen in individual patients. Conclusion-There may a specific role for hsp90 in distinct, clinically active subsets of patients with SLE.
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(Ann Rheum Dis 1993; 52: [436] [437] [438] [439] [440] [441] [442] Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease primarily affecting women of childbearing years. The aetiology probably involves a mosaic of genetic, hormonal, dietary, and complement deficiency factors.' Its prevalence varies from 1:250 among black women in the West Indies and the United States, to 1: 4300 in white subjects (estimated) in New Zealand. The clinical manifestations of SLE are protean, and there is notable mortality and morbidity-treatment with major immunosuppressive drugs often being required for many years. The diversity of clinical features is matched by an apparent diversity of autoantibodies detectable in the serum of patients. A broad range of T cell abnormalities has also been demonstrated. 2 Hsps were initially identified on the basis of their increased synthesis following exposure to raised temperatures.3 ' They have since been shown to be synthesised at increased levels after exposure to a variety of stressful stimuli. Identical proteins (isoforms) are also present constitutively, having a variety of critical functions which can be seen to be readily adapted to protect the cell from damage.5
In normal cells, hsp90 is therefore intracytoplasmic, involved with holding intracellular steroid (glucocorticoid, oestrogen, progesterone) receptors in conformations that prevent the receptor from binding to nuclear DNA until hormone/receptor interaction has occurred.6 7 Members of the 70 kilodalton hsp family appear to prevent inappropriate interactions of proteins which have not reached their final stage of assembly into multiprotein complexes;4 they may also be involved in translocation of proteins within the cell and in antigen presentation.8 Hsp6O aids the transport of proteins into mitochondria by catalysing their unfolding.5
Hsps thus function as common rapid response 'chaperones' for intramolecular and cell membrane events, as well as controlling the transfer of cytoplasmic signals to the nucleus.9
They are vital to the survival of the cell and this idea is supported by their remarkable phylogenetic conservation. 4 0 Hsps have been shown to be immunodominant antigens during bacterial and mycobacterial infections.11 12 Indeed, primitive human T cell repertoires include clones that are directed against hsps, and these may play a beneficial part as a first line of defence against such infections.'3 In addition, low levels of autoantibodies to hsp6O have been found in essentially all human serum samples. '4 Hsps may be at the interface between tolerance and autoimmune disease, if the potentially autoreactive T and B cells described above are triggered to react with endogenous hsps. This could be brought about by increased expression and perhaps cellular relocalisation of endogenous hsps, not only as a disease-initiating event but also as a result of the stresses associated with continuing autoimmune tissue damage.
We have made the preliminary observation that hsp90 is raised in peripheral blood mononuclear cells (PBMC) in 15-20% of patients with active SLE, compared with normal controls and patients with rheumatoid arthritis. '5 This increase was shown to be independent of the presence of fever or of steroid treatment. Significant overexpression of hsps in active SLE has also been documented by others in studies of small numbers of patients. 16 17 In view of the heterogeneity of SLE among patients and within individual patients over time we examined this overexpression further. The objective was to determine whether the raised levels of hsp90 seen in SLE were specific for this protein or whether the other hsps were also increased in parallel. In addition, we wanted to know what the relation was between increased hsps and the disease process.
We therefore examined the expression of other hsps-hsp6O, the highly inducible 72 kilodalton (hsp72) and the constitutive 73 kilodalton (hsp73) members of the hsp7O family4 -in patients with SLE compared with normal controls. Hsp9O was quantified in PBMC from patients over a four year period. Hsps6O, 72, and 73 were quantified in a number of these samples, and compared with results from normal controls. United Kingdom), and PBMC isolated by centrifugation on Ficoll-Paque (Pharmacia, Milton Keynes, United Kingdom). PBMC were resuspended in 1 ml RPMI and counted.
SEPARATION OF MONONUCLEAR CELL POPULATIONS
Some experiments necessitated the separation of PBMC into T, macrophage/monocyte and non-T cell populations. This was achieved by a combination of adherence to plastic plates at 37°C (monocyte/macrophage fraction), and T cell rosetting with neuraminidase-treated sheep red blood cells (Tissue Culture Services, Milton Keynes), followed by centrifugation through Ficoll-Paque (Pharmacia), and incubation of non-T and T cell fractions with red cell lysis buffer (155 mM ammonium chloride, 10 mM ammonium bicarbonate, 0 1 mM EDTA). Protein samples were prepared from cell fractions thus harvested as described for PBMC.
PREPARATION OF PROTEIN SAMPLES
PBMC were pelleted in a microfuge at 6000 rpm for one minute, and resuspended in sample buffer containing 2-3% sodium dodecyl sulphate (SDS), 0-0625 M Tris, 10% glycerol, 5% ,-mercaptoethanol, and bromophenol blue at a concentration of 106 cells to 50 [LI sample buffer. Samples were sonicated forlO s at 2 A, boiled for two minutes and stored at -20°C. PROTEIN 
ELECTROPHORESIS AND IMMUNOBLOTTING
The method used was that of Norton et al6,5
with minor modifications. Protein samples were subjected to vertical, one dimensional SDSpolyacrylamide gel electrophoresis (PAGE). The lower gel consisted of 7% acrylamide (in 1-5 M TRIS, 0.4% SDS, pH 8 Blots were incubated with the MoAb of choice (AC88 at 12-5 ,ug/ml in buffer A, 4B9/89 at 0.125 ,ug/ml in buffer B, StressGen MoAbs at 0 5 ,ug/ml in buffer B) for 2 h at room temperature, and washed as above.
Hsp9O blots were incubated with 125I labelled antimouse F(ab')2 fragments raised in sheep (Amersham International, Buckinghamshire, United Kingdom), at 25 000 cpm/ml in buffer A for 2-5 h at room temperature. They were washed twice in buffer A for 10 minutes each, and finally in TBS for 10 minutes. The blots were dried and autoradiographed using X-OMAT AR film (Kodak, Hemel Hempstead, United Kingdom), with multiple exposures of 3-20 days at -70°C.
Hsp6O, 72, and 73 blots were incubated with antimouse immunoglobulins (raised in rabbit) conjugated to horseradish peroxidase (Dakopatts, Glostrup, Denmark) at a 1 in 300 dilution in buffer B for 2 h at room temperature, and washed as described above. Blots were developed using an enhanced chemiluminescence kit (Amersham), with multiple autoradiograph exposures of 5-30 s at room temperature.
HSP MEASUREMENT Figure 1 shows an autoradiograph of a representative western blot demonstrating hsp90 bands and the corresponding stained/ destained gel. Hsp bands on the autoradiographs and actin bands on the corresponding stained/destained gels were scanned using the VD620 densitometer (Biorad, Hemel Hempstead, United Kingdom) within the linear range.
Levels of hsp were calculated as a ratio of the positive control standard (Jurkat T cell line), which constitutively overexpresses hsps, and which was run on all gels, equalising for intergel and interblot variation. SLE and controls. Hsp9O and hsp72 were significantly raised in patients (p<0 001), whereas hsp6O and hsp73 were not. There was no significant correlation between raised hsp9O and hsp72 in individual SLE samples, nor indeed between levels of any of the hsps (data not shown). This suggests that overexpression of one hsp does not automatically mean that there is overexpression of other hsps in an individual patient sample. Figure 2 shows that there was considerable variation in hsp9O levels in macrophage/ monocyte, T and B cell populations fractionated from PBMC of different SLE samples, even in those patients with raised levels of PBMC. This suggests that simple alteration in the proportion of one cell type with naturally high hsp9O in PBMC from patients with SLE cannot account for our observation of raised hsp9O in these patients. In contrast, there was a fairly consistent pattern of hsp9O expression in the cell types fractionated from PBMC of normal controls, regardless of the hsp9O level in their PBMCthe T cell fractions expressing hsp9O to the highest levels. group.bmj.com on November 7, 2017 -Published by http://ard.bmj.com/ Downloaded from (p<0025 and p<005 respectively), using the UCH/Middlesex scoring system (data not shown). This confirms our original findings. '5 There was no significant increase of hsp72 in active disease scored by this method (data not shown). There was no correlation of either hsp9O or hsp72 with ESR or anti-double stranded DNA (anti-dsDNA) antibody titre in individual SLE samples. Patients taking oral prednisolone, antimalarial drugs, or azathioprine did not have significantly different levels of hsp9O or hsp72 levels compared with patients not taking these drugs (data not shown). Figure 3 shows that patients with active neuropsychiatric SLE according to the BILAG scoring system had significantly raised hsp9O compared with patients with inactive neuropsychiatric SLE (p<0005). Similarly, patients with active cardiorespiratory disease had significantly raised hsp9O compared with patients with inactive cardiorespiratory SLE (p<001). There was no significant difference in hsp9O levels in patients with active compared with inactive SLE in any of the other six BILAG disease categories. Neither hsp72, nor hsp73, nor hsp6O were significantly higher in the active category than in the inactive disease categories (data not shown). Indeed, hsp73 appeared to be higher in the inactive disease categories, significantly so in inactive neuropsychiatric SLE (p<002) and inactive renal SLE (p<0025), compared with active disease in these categories. Thus hsp9O alone is significantly raised in certain clinically active subsets of patients with SLE.
Serial studies in individual patients showed that in 21 patients neuropsychiatric or cardiorespiratory SLE, or both, shifted from active to inactive or vice versa. In 12 (>mean controls + 2SD=02) to low when either or both of these categories became inactive (seven patients), or became high when either or both of these categories became active (five patients).
Discussion
There are compelling arguments to support the hypothesis that hsps are involved in autoimmune phenomena. As cytoplasmic molecules with a physiological role in protein folding and unfolding, endogenous eukaryotic hsps are obvious candidate molecules for a key role in determining the way in which cells interact with the immune system. There is evidence to suggest that members of the hsp7O family may have a critical role in antigen processing. patients with inactive SLE. 30 In that study there also appeared to be a subgroup of patients in whom overexpression of hsp9O correlated to a degree with surface expression of hsp9O. The lack of hsp6O elevation in SLE demonstrated in the current study is matched by lack of surface expression of hsp6O as shown by FACS analysis. In addition, the heterogeneity of hsp9O overexpression by different cell populations in any one patient shown in fig 231 is matched by similar evidence from these surface expression studies.
A consequence of overexpression or surface expression of hsp9O might be the development of anti-hsp9O autoantibodies. This is currently the object of further investigation in our laboratories, with studies being performed upon serum from the same blood samples in which hsps were quantified in this study.
A criticism of efforts to test the hypothesis that hsp overexpression may play a part in autoimmunity, is that one might expect all hsps to be overexpressed in concert merely as a result of the continuing disease process-a 'stressful' situation. The evidence presented here suggests that this is not the case.
We have shown that hsp9O is overexpressed in 32% of patients with SLE (if mean of controls + 2SD = 02 is taken as the upper limit of 'normal'). This is a significant number of patients in a disease as heterogeneous as SLE, and is similar to the number of patients with lupus who, for example, have antibodies to Sm and RNP.32
There is a marked, significant increase of hsp9O in patients with active, compared with inactive neuropsychiatric and cardiorespiratory SLE. Although hsp72 is overexpressed in SLE, there is no correlation between hsp9O and hsp72 in individual patients, and there is no relation between hsp72 and disease activity. In addition, we have shown that hsp6O and hsp73 are not raised in SLE. We have also reported that the small hsp ubiquitin is not overexpressed in SLE. 33 The lack of correlation of hsp9O levels with ESR or anti-dsDNA titre implies that the hsp9O increase is not simply a marker of overall active disease. These data argue for a specific role for hsp9O in The findings presented here, of differential hsp overexpression in SLE, and of hsp9O elevation in certain clinically active subsets of SLE, together with the finding that all cell types in SLE appear to be capable of hsp9O overexpression (fig 2 and 31) , suggest that there may be an underlying genetic alteration in regulation of hsp9O expression, particularly in SLE. Indeed, raised levels of hsp9O correlate with raised transcription rates of this protein in patients with SLE (Twomey et al, unpublished data).
In the current study we have also shown that hsp9O shifts in accord with neuropsychiatric or cardiorespiratory disease activity, or both, in 12/21 (57%) of patients with SLE. Although the relation of these disease activities taken individually, to hsp9O levels, is difficult to interpret, these figures are comparable with those from previous attempts to correlate laboratory parameters with disease activity in SLE. For example, using a combination of circulating immune complex levels, dsDNA binding, lymphocyte counts, and C3 levels, statistical analysis by discriminant function showed that only 44% of cases of SLE could be correctly classified into their clinical disease activity categories.35
To our knowledge there are no reports which examine in detail the comparative expression of hsps, and their relation with disease activity, in autoimmune rheumatic diseases such as SLE. Clearly it is now of importance to understand the processes which produce the specific increase in hsp9O in clinically active subsets of SLE, and their consequences for cellular function and the autoimmune response, in order to elucidate the role of this increase in the aetiology and pathogenesis of SLE. 
